Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects
Authors' conclusion
This study provides valuable insights into the characteristics, treatment expectations and effects experienced by Danish adult users of SEMA-WL.
Study context
- Population
- Adults aged ≥18 years redeeming a prescription for semaglutide for weight loss (Wegovy®, SEMA-WL) at 29 Danish community pharmacies, September–December 20231,013 invited
- Participants
- 559 adults
- Exposure
- <3 months vs 3-5 months vs >5 months
- Outcome
- User characteristics and treatment expectations
Methodological detailsquestionnaire-based survey, multicentre (29 community pharmacies), consecutive sampling
- Questionnaire-based survey
- Multicentre (29 community pharmacies)
- Consecutive sampling
Main finding
As reported in the abstract
- Female
- 78%, n = 434
- Middle-aged (36-65 years)
- 76%, n = 423
- Median BMI at treatment initiation
- 36 (IQR 32-40)
- Personally asked GP to initiate treatment
- 70%, n = 393
- Had not discussed expected treatment duration with GP
- 42%, n = 237
- Expected treatment for a limited time period
- 46%, n = 258
- Expected lifelong treatment
- 11%, n = 64
Observational data: associations, not effects.
Further findings
Self-reported weight loss by treatment duration · self-reported
Safety
- Any side effects
- 59%, n = 330
- Nausea
- 35%, n = 193
- Constipation
- 29%, n = 160
Original publication
Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects. Diabetes Obes Metab. Published 4 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →